RCT | Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy.
7 Jul, 2022 | 12:44h | UTC
Commentary on Twitter
SELECT-AXIS 2 trial – patients with #AS and inadequate response to #bDMARDs. #RCT of upadacitinb vs placebo 14 weeks:
Improved signs and symptoms of active AS and was well tolerated for 14 weeks of treatment in bDMARD-IR patients!https://t.co/Z7fuxiXMDb pic.twitter.com/kGZX9AsaVE— ARD & RMD Open (@ARD_BMJ) July 5, 2022